Effect of sodium ozagrel on the activity of rat CYP2D6

被引:5
|
作者
Wu, Hong
Yu, Weijiang
Huang, Lijun
Wang, Jing
Tang, Xiaobo
Yang, Wei
Liu, Yan
Yu, Huiyan
Zhu, Daling
机构
[1] Harbin Med Univ, Coll Pharm, Harbin 150081, Heilongjiang, Peoples R China
[2] Biopharmaceut Key Lab Heilongjiang Prov, Harbin 150081, Peoples R China
[3] Mudanjiang Med Coll, Mudanjiang 157011, Peoples R China
关键词
ozagrel-1; CYP2D6; microsorne; HPLC; dextromethorphan;
D O I
10.1016/j.ejphar.2007.06.055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to investigate the influence of sodium ozagrel on CYP2D6 (cytochromeP450 2D6) activity. The studies were performed with rat urine and liver microsomes and chemical inhibitors. The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC). The results showed that the metabolism of dextrophan/dextromethorphan in the sodium ozagrel-treated group (37 mg/kg) was higher than that of the control (P < 0.05/6) in both in vivo and in vitro studies (r=0.9811). The rate of dextromethorphan metabolism was inhibited by sodium ozagrel and cimetidine in rat liver microsomes prepared from sodium ozagrel-treated rats and control rats group (sodium ozagrel IC50=26.5 mu M, cimetidine IC50=86.3 mu M in sodium ozagrel-treated group; sodium ozagrel IC50=13.9 mu M, cimetidine IC50=24.8 mu M in control group). The inhibitory effect of sodium ozagrel on CYP2D6 activity was noncompetitive with dextromethorphan with a K-i of 324.94 mu M. Kinetic parameters of the reactions were established by using Lineweaver-Burk with K-m=0.67 mM and V-max = 2.13 pm/min/mg protein for the sodium ozagrel-treated group and K-m=0.29 mM, and V-max =0.91 pm/min/mg protein for the control group, respectively. The expression of CYP2D6 protein in the treated group was higher than that of the control group, as determined by Western blotting. The activity and expression of CYP1A2 did not show obvious differences in the control group and sodium ozagrel treated group. In conclusion, sodium ozagrel metabolism in rats is mediated primarily through CYP2D6, and sodium ozagrel can induce CYP2D6 activity. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [1] The effect of TCAs on CYP2D6 activity in vivo
    Szewczuk-Boguslawska, M.
    Kiejna, A.
    Beszlej, J.
    Orzechowska-Juzwenko, K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S251 - S251
  • [2] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [3] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [4] Effect of different alleles on CYP2D6 activity.
    Borges, S
    Jones, DR
    Bermes, A
    Skaar, TC
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P25 - P25
  • [5] The antitussive effect of dextromethorphan in relation to CYP2D6 activity
    Manap, RA
    Wright, CE
    Gregory, A
    Rostami-Hodjegan, A
    Meller, ST
    Kelm, GR
    Lennard, MS
    Tucker, GT
    Morice, AH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) : 382 - 387
  • [6] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [7] The influence of clomipramine on CYP2D6 activity
    Szewczuk-Boguslawska, Monika
    Kiejna, Andrzej
    Grzesiak, Magdalena
    Beszlej, Jan Aleksander
    Chlebowska, Iwona
    Orzechowska-Juzwenko, Krystyna
    Milejski, Piotr
    PSYCHIATRIA POLSKA, 2007, 41 (02) : 243 - 249
  • [8] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [9] Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10
    Doki, Kosuke
    Shirayama, Yuki
    Sekiguchi, Yukio
    Aonuma, Kazutaka
    Kohda, Yukinao
    Ieda, Masaki
    Homma, Masato
    PHARMACOGENOMICS, 2020, 21 (18) : 1279 - 1288
  • [10] EFFECT OF AGE AND GENOTYPE ON CYP2D6 ACTIVITY IN CHILDREN AND ADOLESCENTS
    Gaedigk, Andrea
    Pearce, Robin E.
    Tay-Sontheimer, Jessica
    Thummel, Kenneth E.
    Lin, Yvonne S.
    Leeder, J. Steven
    DRUG METABOLISM REVIEWS, 2015, 47 : 84 - 85